FLNA

Announcements

Nothing here yet

Daily updates

• Filana Therapeutics announced that the FDA lifted the clinical hold on simufilam, enabling plans for a Phase 2a proof-of-concept study in TSC-associated epilepsy.Sep 22, 2026

FDA designations

Nothing here yet

News

• Filana Therapeutics announces FDA removal of the clinical hold on simufilam, enabling its Phase 2a study in TSC-related epilepsySep 22, 2026
• Filana Therapeutics presented its TSC-related epilepsy program at Eilat XVIII conferenceMay 5, 2026